Table 4. Targeting N. fowleri with inhibitors of known MOA.
| Inhibitors | EC50, μM N. fowleri |
|---|---|
| CYP51 (ERG11) | |
| Posaconazolea | ≤0.01[22] |
| Posaconazole | 0.2±0.08 |
| Isavuconazolea | 0.1[22] |
| Isavuconazole | 1.6±0.03 |
| SMT (ERG6) | |
| Abafungin | 3.1±0.02 |
| Epiminolanosterol | 5.4±0.03 |
| 25-Azacycloartenol | 14.3±0.04 |
| Sterol Δ8−Δ7 isomerase (ERG2) | |
| Tamoxifen | 5.8±0.04 |
| AY9944 | 5.6±0.03 |
| Human σ1 receptor | |
| Fluoxetine (Prozac) | 31.8±0.01 |
| Fluvoxamine (Luvox) | 42% at 50 μM |
| Citalopram (Celexa) | 21% at 50 μM |
| Dextromethorphan (DXM) | 20% at 50μM |
| Standards of care | |
| AmpBa | 0.10±0.01[22] |
| Miltefosine | 54.4±0.01[22] |
asolubilised in SBE-β-CD